PC Diagnostics™

INVICTA DIAGNOSTIC LIMITED

CIN: L86100MH2023PLC414723

Registered Office: 1 Ground Floor, Plot No. 217, Ambavat Bhavan, N.M Joshi Marg, Delisle Road, Mumbai – 400 013. | Email: info@pcdiagnostics.in | Contact: 022 4971 0036

18th September, 2026

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, C-1,
Block G, Bandra Kurla Complex,
Bandra (E), Mumbai 400051

NSE SYMBOL: INVICTA
ISIN: INE0XJ501010

Subject: Outcome of the Meeting of the Board of Directors held on 18th September, 2026 pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of Invicta Diagnostic Limited ("Company"), at its meeting held on Friday, 18th September, 2026, inter alia, considered and approved the proposed business outlook and forward-looking guidance to be communicated by the Chairman & Managing Director and Chief Financial Officer to the Members at the Company's 3rd Annual General Meeting scheduled to be held on Saturday, 19th September, 2026.

The Board noted that the Company has recently completed its Initial Public Offering and raised approximately ₹28.12 crore through fresh issue of equity shares, and is deploying the IPO proceeds towards the objects of the issue and its growth and expansion initiatives. The Company has expanded its operations to Dadar, Pune, Nashik and Shegaon and currently has 11 diagnostic centres and 2 centralised laboratories, with operations being commenced and ramped up in a phased manner.

The proposed communication will cover the Company's business outlook, growth and expansion strategy, strategic priorities, deployment of capital and indicative financial guidance, including the focus on ramping up newly established centres, improving utilisation and operational efficiency and achieving sustainable growth.

The Board noted that such guidance represents management's current indicative targets and outlook based on prevailing business plans, expectations and assumptions and should not be construed as a guarantee, assurance or forecast of future financial performance. Actual results may vary due to, inter alia, patient volumes, utilisation levels, pace of ramp-up, market and economic conditions, regulatory developments, competition and other risks and uncertainties.

The meeting commenced at 11.00 AM and concluded at 1.15 PM

This is for your information and records.

Thanking you.

Yours Faithfully,
For Invicta Diagnostic Limited

Sanket Vinod Jain

Digitally signed by Sanket Vinod Jain
Date: 2026.09.18 13:28:59 +05'30'

Sanket Vinod Jain
Managing Director
DIN: 08299039
Place: Mumbai

3rd Annual General Meeting of Invicta Diagnostic Limited

A. Speech of Mr. Sanket Jain, Chairman and Managing Director

Dear Members,

A very warm welcome to all of you to the 3rd Annual General Meeting of Invicta Diagnostic Limited. On behalf of the Board and the entire Invicta family, I sincerely thank you for your continued trust, confidence and support.

FY 2025–26 was an important year for the Company, marked by the successful completion of our IPO and listing on the NSE Emerge platform. The Company raised approximately ₹28.12 crore through the fresh issue, which has strengthened our capital base and also increased our responsibility towards transparency, governance and long-term value creation.

During the year, we commenced operations at our Dadar centre and subsequently expanded into Pune, Nashik and Shegaon. With these additions, our network has grown to 11 diagnostic centres and 2 centralised laboratories. We remain focused on expanding our presence across Maharashtra while improving the utilisation and efficiency of our existing infrastructure.

As part of our disciplined growth strategy, the Company also diversified the utilisation of a portion of its IPO proceeds and subsequently acquired a 51% stake in Vinchurkar Diagnostics Private Limited in May 2026, making it a subsidiary. We believe this acquisition will complement our expansion strategy and strengthen our presence in Maharashtra.

Going forward, our focus will remain on quality healthcare, better utilisation of our infrastructure, technology adoption, patient-centric services, selective expansion and disciplined capital allocation. As a listed company, we remain firmly committed to transparency, accountability and sustainable long-term value creation.

I sincerely thank our shareholders, Board members, doctors, employees, auditors, bankers, advisors, business partners and healthcare professionals for their valuable contribution. Most importantly, I thank our patients and healthcare partners for their continued trust in us.

We have entered a new chapter in our journey, and with your continued support, we look forward to building a stronger, more integrated and sustainable diagnostic healthcare platform.

Thank you.

B. Speech of Mr. Rohit Srivastava, CFO

Respected Chairman, Members of the Board and Esteemed Shareholders,

Good afternoon to everyone.

I am pleased to present the key financial highlights of Invicta Diagnostic Limited for the financial year ended March 31, 2026.

FY 2025–26 was an important year for the Company, marked by growth in our operations, successful completion of the IPO and strengthening of our financial position.

On a standalone basis, the Company recorded total income of Rs. 2,140.91 Lakhs as against Rs. 1,773.42Lakhs in the previous year. The Company earned Profit Before Tax of Rs. 725.41 Lakhs and Profit After Tax of Rs.552.81 Lakhs during the year under review, as compared to Profit Before Tax of Rs. 668.39 Lakhs and Profit After Tax of Rs. 522.74 Lakhs, respectively, in the previous year.

On a consolidated basis, Company generated consolidated total income of Rs. 3,304.19 Lakhs as against Rs. 3018.14 Lakhs in the previous year. The Company earned Consolidated Profit Before Tax of Rs. 700.84 Lakhs and Consolidated Profit After Tax of Rs. 487.32 Lakhs during the year under review, as compared to Consolidated Profit Before Tax of Rs. 656.36 Lakhs and Consolidated Profit After Tax of Rs. 492.95 Lakhs, respectively, in the previous year.

During the year, the Company also commenced operations at its Dadar centre, followed by expansion into Pune, Nashik and Shegaon after the year-end. The Company now has 11 diagnostic centres and 2 centralised laboratories. Our immediate focus is on ramping up these centres, improving utilisation and enhancing operational efficiency.

Going forward, our financial priorities will remain focused on revenue growth, profitability, efficient utilisation of capital, working capital management and disciplined capital allocation. We will continue to invest selectively in infrastructure, technology and advanced diagnostic capabilities while maintaining strong financial controls and governance.

Based on our current business plans and management expectations, we are targeting consolidated revenue in the range of approximately ₹45 to ₹50 crore, with an EBITDA margin of around 25%.

I would like to clarify that these figures represent the management's current indicative business targets and outlook and should not be construed as a guarantee, assurance or forecast of future financial performance. Actual results may vary depending on business performance, patient volumes, market conditions, economic factors, regulatory developments and other risks and uncertainties.

Our objective remains to achieve profitable and sustainable growth while continuing to strengthen the Company's fundamentals and deliver long-term value to all our stakeholders.

To conclude, FY 2025–26 has laid a strong foundation for the Company's next phase of growth. Our focus now is to convert our expanded platform and strengthened capital base into sustainable and profitable operating performance.

I sincerely thank our shareholders, Board, management, employees, auditors, bankers, advisors and all other stakeholders for their continued support and confidence.

Thank you, and I wish the Company and all its shareholders continued success.